AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (AIM) highlighted a BioTuesdays feature examining Ampligen’s potential as maintenance therapy after first-line chemotherapy for metastatic pancreatic cancer.
Final Ampligen dosing is complete in DURIPANC, which evaluates Ampligen with AstraZeneca’s Imfinzi; primary and secondary endpoint reporting remains pending. AIM is working toward further clinical development. In an exploratory Named Patient Program analysis, 39 patients with a neutrophil-to-lymphocyte ratio, an immune-cell measure, below 4.5 had median overall survival of 34.8 months from the start of FOLFIRINOX chemotherapy. The program was not a controlled clinical trial, and historical comparisons do not establish efficacy. The feature also discusses patents, pancreatic cancer orphan drug designations and potential financing or pharmaceutical partnerships to support a pivotal Phase 3 study.
AIM ImmunoTech (AIM) highlighted recent media coverage examining its investigational drug Ampligen’s potential antiviral and post-viral therapeutic applications.
Healthcare Business Today featured CEO Tom Equels discussing preparedness for viral outbreaks, while MediTech Today examined AIM’s Long COVID patent protection. AIM describes Ampligen’s possible applications as including emerging viral threats such as Ebola Virus Disease and post-viral conditions. Ampligen is also being studied in the company’s oncology clinical program, which focuses on pancreatic cancer.
AIM ImmunoTech (AIM) highlighted Ampligen’s pancreatic cancer development strategy as the Phase 2 DURIPANC trial completed final Ampligen dosing.
DURIPANC evaluates Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. AIM expects topline results in the first quarter of 2027. Interim reports suggest activation of both innate and adaptive immune responses; the combination was reported as well-tolerated, with patients reporting high quality of life throughout treatment.
AIM also completed a Netherlands-approved Named Patient Program involving 57 patients with radiologically stable pancreatic cancer after FOLFIRINOX, who received Ampligen as maintenance treatment. The company described survival, safety and quality-of-life findings as encouraging.
AIM ImmunoTech (AIM) released a CEO Corner video discussing Ampligen’s potential role alongside or after other pancreatic cancer therapies.
An exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio (NLR), a blood-cell ratio, below 4.5 found median overall survival of 34.8 months from the start of FOLFIRINOX chemotherapy. These patients received Ampligen maintenance after radiologically stable disease. Differences in patient selection, disease stage, treatment setting and survival measurement prevent direct comparisons with separate therapy trials.
The ongoing Phase 2 DURIPANC study evaluates Ampligen with AstraZeneca’s durvalumab in metastatic pancreatic cancer. Its primary endpoint is clinical benefit rate at 24 weeks after combination therapy starts. AIM expects topline results in Q1 2027 and overall survival analysis to begin in Q3 2027.
AIM ImmunoTech (AIM) released a CEO letter outlining how its investigational drug Ampligen could fit into pancreatic cancer treatment following the FDA approval of daraxonrasib for metastatic disease.
Ampligen is described as a TLR3 agonist designed to activate innate immunity and reshape the tumor microenvironment, in contrast to daraxonrasib, which directly inhibits RAS. In a Dutch government‑approved Named Patient Program, Ampligen monotherapy in patients with a blood neutrophil‑to‑lymphocyte ratio below 4.5 was associated with a median overall survival of 34.8 months, versus 12.5 months in well‑matched historical controls, an observed difference of 22.3 months. AIM sees potential for Ampligen both as monotherapy and in combinations such as with checkpoint inhibitors.
The ongoing Phase 2 DURIPANC trial is testing Ampligen plus durvalumab in patients with pancreatic cancer stable after FOLFIRINOX, with topline data expected in Q1 2027 and overall‑survival analysis in Q3 2027. Ampligen already has FDA and EMA orphan designations for pancreatic cancer, and AIM plans to use upcoming data to define a potential pivotal Phase 3 trial.
On September 9, 2026, AIM ImmunoTech (AIM) released a new CEO Corner video outlining its scientific strategy and clinical progress with Ampligen (rintatolimod) in pancreatic cancer.
The video highlights Ampligen, an investigational TLR3 agonist designed to activate innate immunity and reshape the tumor microenvironment to potentially enhance responses to PD-1 and PD-L1 checkpoint inhibitors. The company focuses on the ongoing Phase 2 DURIPANC study, which evaluates Ampligen combined with AstraZeneca’s durvalumab as maintenance therapy after standard-of-care treatment. AIM also discusses biomarker research, collaborations, IP expansion, regulatory engagement, and upcoming DURIPANC milestones, including primary endpoint analyses and overall survival follow-up.
AIM ImmunoTech (AIM) announced expanded patent protection for its drug Ampligen in the treatment of Long COVID across major European markets and the United Kingdom, with coverage expected to run through June 2041.
The protection consists of three forms of patents in Europe and the UK that became final after a nine‑month opposition period under the European Patent Convention closed on August 25, 2026, with no opposition filed. This follows a newly issued U.S. patent covering Ampligen in combination with pembrolizumab for cancer treatment, broadening Ampligen’s global intellectual property estate across multiple therapeutic areas.
The granted claims cover therapeutic double stranded RNA for treating Long COVID, including specific dosing regimens and intranasal, intravenous and inhalation administration, with Ampligen included in this scope. The company reports that Ampligen has undergone extensive clinical and preclinical testing in more than 1,200 patients receiving over 100,000 doses, with no drug-related deaths and favorable safety profiles across several routes of administration.
AIM ImmunoTech (NYSE American: AIM) announced that the U.S. Patent and Trademark Office has granted a new patent covering the use of its drug Ampligen (rintatolimod) in combination with the PD‑1 checkpoint inhibitor pembrolizumab (Keytruda) for cancer treatment, expiring on December 20, 2039.
The broadest claim covers synergistic combination therapy in which Ampligen plus pembrolizumab produces a greater anti‑cancer effect than either drug alone, across cancer types. Additional claims name multiple cancers, including pancreatic, ovarian, colorectal, breast (including triple‑negative), lung, melanoma, bladder, renal cell carcinoma, head and neck tumors, and skin cancer. AIM also holds related U.S., Netherlands and Japanese patents extending Ampligen’s combination oncology IP with PD‑1/PD‑L1 inhibitors into 2039.
AIM ImmunoTech (NYSE American: AIM) announced its participation in the Virtual Investor “Why Now” on‑demand conference, where CEO Thomas Equels presented the company’s investment thesis and clinical progress. The webcast highlights advancement of Ampligen in the Phase 2 DURIPANC trial for metastatic pancreatic cancer, including completion of enrollment ahead of schedule, dosing of the final patient, and the planned transition to primary endpoint evaluation in Q4 2026, with topline results expected in Q1 2027. The video webcast is now available for on‑demand viewing.
AIM ImmunoTech (NYSE American: AIM) announced that CEO Thomas K. Equels authored a new article in Breaking Defense titled “Biodefense is force protection: Ready today, prepared for tomorrow,” published August 11, 2026. Equels argues that biodefense should be integrated into military force protection planning, with broad-spectrum prophylactic and early-onset antiviral countermeasures evaluated before novel biological threats emerge.
The article highlights government-funded preclinical studies of AIM’s investigational drug Ampligen (rintatolimod). Research at USAMRIID reported a rintatolimod-treated mouse cohort with 100% survival in a lethal Ebola model versus 100% mortality in controls, supporting further mechanism-of-action evaluation across Ebola variants. Additional preclinical work at Utah State University following the 2003 SARS outbreak supported further evaluation of Ampligen as a potential early-onset antiviral against SARS-related coronaviruses.